Skip to content
2000
image of A Population Pharmacokinetics Model of Busulfan in Pediatric Patients with Thalassemia Major

Abstract

Purpose

This research aimed to establish a population pharmacokinetic (PPK) model for busulfan (Bu) in Chinese pediatric patients with thalassemia major. We analyzed pharmacokinetic (PK) parameter variability and explored potential covariates affecting Bu disposition using patient data. These findings are intended to support the optimization and personalization of Bu dosage regimens for children with thalassemia major.

Methods

Concentration-time samples were collected retrospectively from 62 pediatric patients with thalassemia major. These patients had previously received intravenous Bu as a preparatory regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). A PPK model of Bu was developed through nonlinear mixed-effects modeling. This modeling process, conducted using NONMEM software, concurrently involved data analysis and examination of the effect of covariates on Bu pharmacokinetics. For validation purposes, the resulting model was evaluated against an external dataset consisting of 20 individuals.

Results

The pharmacokinetic results were optimally analyzed using a model that incorporated a one-compartment model with first-order elimination. Body surface area (BSA) was subsequently identified as the most significant factor influencing both Bu clearance (CL) and volume of distribution (V). Diagnostic evaluations, encompassing goodness-of-fit plots, normalized prediction distribution errors, and visual predictive checks, confirmed the satisfactory fit and predictability of the final PPK model. Moreover, prediction-based diagnostic indices (MDPE%, 15.75; MAPE%, 22.26; F20%, 45.71; and F30%, 58.57) from external validation showed that no significant bias was detected when comparing the model's predicted concentrations against the observed data.

Conclusion

The present study developed the first PPK model characterizing the pharmacokinetics of Bu specifically in children with thalassemia major. This study's final PPK model demonstrated that BSA was the key predictive covariate for CL and V.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002402673251003055700
2025-10-15
2025-12-14

  • From This Site

    /content/journals/cdm/10.2174/0113892002402673251003055700
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Baird D.C. Batten S.H. Sparks S.K. Alpha- and Beta-Thalassemia: Rapid evidence review. Am. Fam. Physician 2022 105 3 272 280 35289581
    [Google Scholar]
  2. Sonkawade N.D. Kinikar A.A. Kulkarni R.K. Dawre R.M. Valvi C.T. Kamath P.A. Screening of extended family members of Thalassemia major children as a Thalassemia preventive strategy. Ethiop. J. Health Sci. 2022 32 6 1203 1210 10.4314/ejhs.v32i6.18 36475260
    [Google Scholar]
  3. Li C.G. Li C.F. Li Q. Li M. Thalassemia incidence and treatment in China with special reference to Shenzhen City and Guangdong province. Hemoglobin 2009 33 5 296 303 10.3109/03630260903211698 19814675
    [Google Scholar]
  4. Lai K. Huang G. Su L. He Y. The prevalence of thalassemia in mainland China: Evidence from epidemiological surveys. Sci. Rep. 2017 7 1 920 10.1038/s41598‑017‑00967‑2 28424478
    [Google Scholar]
  5. Xu X. Wu X. Epidemiology and treatment of beta Thalassemia major in China. Pediatr. Investig. 2020 4 1 43 47 10.1002/ped4.12154 32851341
    [Google Scholar]
  6. Oikonomopoulou C. Goussetis E. HSCT remains the only cure for patients with transfusion-dependent thalassemia until gene therapy strategies are proven to be safe. Bone Marrow Transplant. 2021 56 12 2882 2888 10.1038/s41409‑021‑01461‑0 34531544
    [Google Scholar]
  7. Abbasi N. Vadnais B. Knutson J.A. Blough D.K. Kelly E.J. O’Donnell P.V. Deeg H.J. Pawlikowski M.A. Ho R.J.Y. McCune J.S. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J. Clin. Pharmacol. 2011 51 10 1429 1438 10.1177/0091270010382915 21135089
    [Google Scholar]
  8. Palmer J. McCune J.S. Perales M.A. Marks D. Bubalo J. Mohty M. Wingard J.R. Paci A. Hassan M. Bredeson C. Pidala J. Shah N. Shaughnessy P. Majhail N. Schriber J. Savani B.N. Carpenter P.A. Personalizing busulfan-based conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol. Blood Marrow Transplant. 2016 22 11 1915 1925 10.1016/j.bbmt.2016.07.013 27481448
    [Google Scholar]
  9. He Z. Wang Y. Zhu H. Chen Y. Ye C. Ou J. Junyan, ; Yu, X. Population pharmacokinetics of busulfan in pediatric patients: Opti-mization of a four‐times‐daily dosing regimen based on EBMT rec-ommendations Pediatr. Blood Cancer 2025 e31969, e31969. 10.1002/pbc.31969 40781807
    [Google Scholar]
  10. Nguyen L. Fuller D. Lennon S. Leger F. Puozzo C.I.V. busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004 33 10 979 987 10.1038/sj.bmt.1704446 15064687
    [Google Scholar]
  11. Schreib K.M. Bräm D.S. Zeilhofer U.B. Müller D. Güngör T. Krämer S.D. Hauri-Hohl M.M. Population pharmacokinetic modeling for twice-daily intravenous busulfan in a large cohort of pediatric patients undergoing hematopoietic stem cell transplantation—A 10-year single-center experience. Pharmaceutics 2023 16 1 13 10.3390/pharmaceutics16010013 38276491
    [Google Scholar]
  12. Savic R.M. Cowan M.J. Dvorak C.C. Pai S.Y. Pereira L. Bar-telink I.H. Boelens J.J. Bredius R.G.M. Wynn R.F. Cuvelier G.D.E. Shaw P.J. Slatter M.A. Long-Boyle J. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2013 19 11 1608 1614 10.1016/j.bbmt.2013.08.014 24029650
    [Google Scholar]
  13. Del Valle-Moreno P. Suarez-Casillas P. Mejías-Trueba M. Ciudad-Gutiérrez P. Guisado-Gil A. Gil-Navarro M. Herrera-Hidalgo L. Model-informed precision dosing software tools for dosage regimen individualization: A scoping review. Pharmaceutics 2023 15 7 1859 10.3390/pharmaceutics15071859 37514045
    [Google Scholar]
  14. Neroutsos E. Nalda-Molina R. Paisiou A. Zisaki K. Goussetis E. Spyridonidis A. Kitra V. Grafakos S. Valsami G. Dokoumetzidis A. Development of a population pharmacokinetic model of busulfan in children and evaluation of different sampling schedules for precision dosing. Pharmaceutics 2022 14 3 647 10.3390/pharmaceutics14030647 35336021
    [Google Scholar]
  15. Bartelink I.H. Lalmohamed A. Bognar T. Nur E. Boelens J.J. Optimizing allogeneic hematopoietic cell transplantation outcomes through busulfan PK/PD. Transplant. Cell. Ther. 2025 31 8 477 479 10.1016/j.jtct.2025.07.008 40759455
    [Google Scholar]
  16. Bartelink I.H. van Kesteren C. Boelens J.J. Egberts T.C.G. Bierings M.B. Cuvelier G.D.E. Wynn R.F. Slatter M.A. Chiesa R. Danhof M. Knibbe C.A.J. Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther. Drug Monit. 2012 34 5 574 583 10.1097/FTD.0b013e31826051bb 22972539
    [Google Scholar]
  17. Trame M.N. Bergstrand M. Karlsson M.O. Boos J. Hempel G. Population pharmacokinetics of busulfan in children: Increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin. Cancer Res. 2011 17 21 6867 6877 10.1158/1078‑0432.CCR‑11‑0074 21918171
    [Google Scholar]
  18. Bleyzac N. Souillet G. Magron P. Janoly A. Martin P. Bertrand Y. Galambrun C. Dai Q. Maire P. Jelliffe R.W. Aulagner G. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001 28 8 743 751 10.1038/sj.bmt.1703207 11781625
    [Google Scholar]
  19. Tse W.T. Duerst R. Schneiderman J. Chaudhury S. Jacobsohn D. Kletzel M. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant. 2009 44 3 145 156 10.1038/bmt.2008.437 19182832
    [Google Scholar]
  20. Choi B. Kim M.G. Han N. Kim T. Ji E. Park S. Kim I.W. Oh J.M. Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. Pharmacogenomics 2015 16 14 1585 1594 10.2217/pgs.15.98 26419450
    [Google Scholar]
  21. Salvaris R. Salman S. O’Halloran S. Joyce D. Mathew N. Cooney J. Wright M. Cannell P. Purtill D. Evaluating the efficacy, toxicity and pharmacokinetic profile of oral busulfan in allogeneic stem cell transplant patients. Blood Cell. Ther. 2022 5 2 61 68 10.31547/bct‑2021‑019 36710948
    [Google Scholar]
  22. Yang Y. Wang C. Chen Y. Wang X. Jiao Z. Wang Z. External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients. Eur. J. Pharm. Sci. 2023 186 106416 10.1016/j.ejps.2023.106416 37119861
    [Google Scholar]
  23. Nadella T.R. Suryadevara V. Lankapalli S.R. Mandava V.B.R. Bandarupalli D. LC–MS/MS method development for quantification of busulfan in human plasma and its application in pharmacokinetic study. J. Pharm. Biomed. Anal. 2016 120 168 174 10.1016/j.jpba.2015.12.024 26736033
    [Google Scholar]
  24. Xiao Y. Li X. Fu X. A rapid and simple LC–MS/MS method for personalized busulfan dosing in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). Clin. Chim. Acta 2018 479 190 195 10.1016/j.cca.2018.01.020 29341904
    [Google Scholar]
  25. Liu M. Qin J. Chu X. Chen N. Jie Q. Zheng S. Population pharmacokinetic study and application of ticagrelor and AR-C124910XX after percutaneous coronary intervention in Chinese patients with acute coronary syndrome Int. J. Clin. Pharmacol. Ther. 2024 62 9 412 422 10.5414/CP204550 39037109
    [Google Scholar]
  26. Wang X. Wang Y. Yao F. Chen S. Hou Y. Zheng Z. Luo J. Qiu B. Li Z. Wang Y. Wu Z. Lan J. Chen C. Pharmacokinetics of Linezolid dose adjustment for creatinine clearance in critically ill patients: A multicenter, prospective, open-label, observational study. Drug Des. Devel. Ther. 2021 15 2129 2141 10.2147/DDDT.S303497 34040351
    [Google Scholar]
  27. Cai R. Zhang L. Wu T. Huang Y. Lu J. Huang T. Wu Y. Wu D. Qi J. Niu L. Xiao Y. Chen X. Liu Y. Luo Y. Liu T. Population pharmacokinetics of cyclosporine A in pediatric patients with thalassemia undergoing allogeneic hematopoietic stem cell transplantation. Eur. J. Clin. Pharmacol. 2024 80 5 685 696 10.1007/s00228‑024‑03641‑5 38329479
    [Google Scholar]
  28. Grassedonio E. Incorvaia L. Guarneri M. Guagnini F. Midiri M. Prevention of post-contrast kidney injury in patients with cancer. Drugs Context 2024 13 1 10 10.7573/dic.2023‑11‑2 38510312
    [Google Scholar]
  29. Zhao C.Y. Jiao Z. Mao J.J. Qiu X.Y. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br. J. Clin. Pharmacol. 2016 81 5 891 907 10.1111/bcp.12830 26574188
    [Google Scholar]
  30. Shao D. Li J. Hu T. Zhang Z. Zhang; li, J.; Cao, J.; Feng, S.; Tang, R.; Zhong, D.; Song, Z.; Yue, M.; Hu, M.; Xuan, L.; Zhai, M.; Zhang, H.; Wang, X.; Shi, X.; Liu, R. Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring. Bone Marrow Transplant. 2022 57 3 473 478 10.1038/s41409‑021‑01545‑x 35039622
    [Google Scholar]
  31. Kishimoto K. Hasegawa D. Irie K. Okada A. Nakamura S. Tamura A. Yamamoto N. Kozaki A. Saito A. Ishida T. Fukushima S. Kosaka Y. Pharmacokinetic analysis for model‐supported therapeutic drug monitoring of busulfan in Japanese pediatric hematopoietic stem cell transplantation recipients. Pediatr. Transplant. 2020 24 4 e13696 10.1111/petr.13696 32196880
    [Google Scholar]
  32. Gaziev J. Nguyen L. Puozzo C. Mozzi A.F. Casella M. Perrone Donnorso M. Gravina P. Sodani P. Marziali M. Isgrò A. Simone M.D. Andreani M. Formosa A. Testi M. Federici G. Bernardini S. Lucarelli G. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: A prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010 115 22 4597 4604 10.1182/blood‑2010‑01‑265405 20237319
    [Google Scholar]
  33. Faraci M. Tinelli C. Lanino E. Giardino S. Leoni M. Ferretti M. Castagnola E. Broglia M. De Silvestri A. Di Martino D. Bartoli A. Monitoring of busulphan concentrations in children undergone hematopoietic stem cell transplantation: Unicentric experience over 10 years. Eur. J. Drug Metab. Pharmacokinet. 2018 43 2 173 181 10.1007/s13318‑017‑0431‑0 28801891
    [Google Scholar]
  34. Takahashi T. Jaber M.M. Brown S.J. Al-Kofahi M. Population pharmacokinetic model of intravenous busulfan in hematopoietic cell transplantation: Systematic review and comparative simulations. Clin. Pharmacokinet. 2023 62 7 955 968 10.1007/s40262‑023‑01275‑x 37415003
    [Google Scholar]
  35. Poonkuzhali B. Srivastava A. Quernin M.H. Dennison D. Aigrain E.J. Kanagasabapathy A.S. Krishnamoorthy R. Chandy M. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999 24 1 5 11 10.1038/sj.bmt.1701814 10435727
    [Google Scholar]
  36. Gürlek Gökçebay D. Azik F. Ozbek N. Isik P. Avci Z. Tavil B. Kara A. Tunc B. Clinical comparison of weight‐ and age‐based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. Pediatr. Transplant. 2015 19 3 307 315 10.1111/petr.12430 25661259
    [Google Scholar]
  37. Yuan J. Sun N. Feng X. He H. Mei D. Zhu G. Zhao L. Optimization of busulfan dosing regimen in pediatric patients using a population pharmacokinetic model incorporating GST mutations. Pharm. Genomics Pers. Med. 2021 14 253 268 10.2147/PGPM.S289834 33623415
    [Google Scholar]
  38. McCune J.S. Bemer M.J. Barrett J.S. Scott Baker K. Gamis A.S. Holford N.H.G. Busulfan in infant to adult hematopoietic cell transplant recipients: A population pharmacokinetic model for initial and Bayesian dose personalization. Clin. Cancer Res. 2014 20 3 754 763 10.1158/1078‑0432.CCR‑13‑1960 24218510
    [Google Scholar]
  39. Pawlowska A.B. Blazar B.R. Angelucci E. Baronciani D. Shu X.O. Bostrom B. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant. 1997 20 11 915 920 10.1038/sj.bmt.1701001 9422469
    [Google Scholar]
  40. Mahomedradja R.F. Bognàr T. van Schie K.E. Kuipers I.T. de Witte M.A. Kuball J.H.E. Nur E. Wilhelm B.J. Heerma van Voss M.R. Franken L. Lalmohamed A. Swart E.N.L. de Leeuw D.C. Bartelink I.H. Model‐informed precision dosing of busulfan for children and adults undergoing allogeneic hematopoietic stem cell transplantation: A critical evaluation of current PK models and dose recommendations. Clin. Pharmacol. Ther. 2025 118 3 723 734 10.1002/cpt.3748 40545743
    [Google Scholar]
  41. Puangpetch A. Thomas F. Anurathapan U. Pakakasama S. Hongeng S. Rachanakul J. Prommas S. Nuntharadthanaphong N. Chatelut É. Sukasem C. Le Louedec F. Model-informed precision dosing of intravenous busulfan in Thai pediatrics undergoing hematopoietic stem cell transplantation. Ther. Drug Monit. 2024 46 6 778 785 10.1097/FTD.0000000000001225 38758634
    [Google Scholar]
  42. Kim M.G. Kwak A. Choi B. Ji E. Oh J.M. Kim K. Effect of glutathione S‐transferase genetic polymorphisms on busulfan pharmacokinetics and veno‐occlusive disease in hematopoietic stem cell transplantation: A meta‐analysis. Basic Clin. Pharmacol. Toxicol. 2019 124 6 691 703 10.1111/bcpt.13185 30511436
    [Google Scholar]
  43. Gibbs J.P. Murray G. Risler L. Chien J.Y. Dev R. Slattery J.T. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res. 1997 57 24 5509 5516 9407960
    [Google Scholar]
  44. Ansari M. Huezo-Diaz P. Rezgui M.A. Marktel S. Duval M. Bittencourt H. Cappelli B. Krajinovic M. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in Thalassemia pediatric patients. Bone Marrow Transplant. 2016 51 3 377 383 10.1038/bmt.2015.321 26691424
    [Google Scholar]
  45. Nava T. Kassir N. Rezgui M.A. Uppugunduri C.R.S. Huezo-Diaz Curtis P. Duval M. Théoret Y. Daudt L.E. Litalien C. Ansari M. Krajinovic M. Bittencourt H. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. Br. J. Clin. Pharmacol. 2018 84 7 1494 1504 10.1111/bcp.13566 29469189
    [Google Scholar]
  46. Nishikawa T. Yamaguchi H. Ikawa K. Nakayama K. Higashi E. Miyahara E. Abematsu T. Nakagawa S. Kodama Y. Tanabe T. Shigemi A. Shinkoda Y. Okamoto Y. Takeda Y. Kawano Y. Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children. Pediatr. Int. 2019 61 6 558 565 10.1111/ped.13859 30963629
    [Google Scholar]
  47. Long-Boyle J.R. Savic R. Yan S. Bartelink I. Musick L. French D. Law J. Horn B. Cowan M.J. Dvorak C.C. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: A model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther. Drug Monit. 2015 37 2 236 245 10.1097/FTD.0000000000000131 25162216
    [Google Scholar]
/content/journals/cdm/10.2174/0113892002402673251003055700
Loading
A Population Pharmacokinetics Model of Busulfan in Pediatric Patients with Thalassemia Major
Bentham Science Publishers ; https://doi.org/10.2174/0113892002402673251003055700
/content/journals/cdm/10.2174/0113892002402673251003055700
/content/journals/cdm/10.2174/0113892002402673251003055700
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: individualized therapy ; therapeutic drugmonitoring ; Busulfan ; population pharmacokinetics ; hematopoietic stem cell transplantation ; thalassemia major

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test